Candesartan Cilexetil Drug Global Market Report 2025

The rising prevalence of hypertension is expected to drive the growth of the candesartan cilexetil drug market in the future. Hypertension, commonly known as high blood pressure, is a condition in which the force of blood against the artery walls is consistently too high, typically defined by a reading of 130/80 mmHg or higher. The increasing prevalence of hypertension is largely attributed to unhealthy lifestyle choices, including poor diet, insufficient physical activity, and high-stress levels. Candesartan cilexetil helps manage hypertension by blocking the action of angiotensin II, a hormone that narrows blood vessels, thereby relaxing the vessels and lowering blood pressure. For instance, in October 2024, the Centers for Disease Control and Prevention (CDC), a US-based government agency, reported a significant increase in hypertension prevalence, rising by 124.48% from the 18-39 age group to the 40-59 age group, and by 36.38% from the 40-59 age group to individuals aged 60 and above, between August 2021 and August 2023. Therefore, the rising burden of hypertension is boosting the demand for candesartan cilexetil.

The rising incidence of cardiovascular disorders is expected to fuel the growth of the candesartan cilexetil drug market moving forward. Cardiovascular disorders are health issues that affect the heart or blood vessels, impairing heart function. The increase in cardiovascular disorders is mainly due to a lack of physical activity, which can lead to obesity, high blood pressure, and poor cardiovascular health, ultimately reducing the heart and circulatory system's efficiency. Candesartan cilexetil helps manage cardiovascular conditions by lowering blood pressure, easing the strain on the heart, and reducing the risk of complications such as heart failure, stroke, and kidney damage. For example, in January 2025, the British Heart Foundation, a UK-based cardiovascular research organization, reported that about 7.6 million people in the UK suffer from heart and circulatory diseases, including around 4 million men and 3.6 million women. These diseases contribute to nearly 27% of all deaths in the country, leading to over 170,000 fatalities annually, or about 480 deaths per day. As a result, the increasing prevalence of cardiovascular disorders is driving the growth of the candesartan cilexetil drug market.

Key players in the candesartan cilexetil drug market are focusing on developing innovative formulations, such as combination therapies with other antihypertensive medications and extended-release versions, to enhance patient adherence and improve treatment outcomes. Hypertension treatment includes medications, lifestyle changes, and other interventions aimed at lowering blood pressure to reduce the risk of complications such as heart disease, stroke, and kidney damage. For instance, in March 2025, Scienture Inc., a US-based pharmaceutical company, received approval from the US Food and Drug Administration (FDA) for its New Drug Application (NDA) for SCN-102, branded as Arbli, a losartan potassium oral suspension (10 mg/mL). This angiotensin II receptor blocker (ARB) formulation offers an alternative for patients who have difficulty swallowing tablets, particularly among pediatric and geriatric populations. The launch of this product highlights the growing interest in alternative dosage forms in the antihypertensive market and signals a shift toward more personalized, patient-friendly drug delivery systems.

Major players in the candesartan cilexetil drug market are Merck & Co. Inc., Bayer AG, Novartis AG, AstraZeneca plc, GSK plc, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Sandoz Group AG, Viatris Inc., Sun Pharmaceutical Industries Limited, Aurobindo Pharma Limited, Dr. Reddy's Laboratories Limited, Cipla Limited, Zydus Lifesciences Ltd., Hetero Drugs Limited, Torrent Pharmaceuticals Limited, Macleods Pharmaceuticals Ltd., Alembic Pharmaceuticals Limited, Oubari Pharmaceutical Co.

North America was the largest region in the candesartan cilexetil drug market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in candesartan cilexetil drug report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the candesartan cilexetil drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The candesartan cilexetil drug market consists of sales of atacand, candesartan tablets, and oral tablets. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

Candesartan cilexetil is an angiotensin II receptor antagonist primarily used to treat high blood pressure and heart failure. It works by blocking the effects of angiotensin II, helping to relax blood vessels and lower blood pressure.

The main product types of candesartan cilexetil include tablets, capsules, and other forms. Tablets are solid dosage forms that typically consist of a mixture of active pharmaceutical ingredients and excipients, compressed into a small, convenient shape. Candesartan cilexetil is used for multiple indications, including hypertension, heart failure, diabetic nephropathy, and left ventricular hypertrophy. The available dosage strengths are 4 mg, 8 mg, 16 mg, and 32 mg. The drug is distributed through various channels, including hospital pharmacies, retail pharmacies, online pharmacies, and healthcare facilities. It is used for a range of applications in adults, children, and adolescents.

The candesartan cilexetil drug market research report is one of a series of new reports that provides candesartan cilexetil drug market statistics, including the candesartan cilexetil drug industry global market size, regional shares, competitors with the candesartan cilexetil drug market share, detailed candesartan cilexetil drug market segments, market trends, and opportunities, and any further data you may need to thrive in the candesartan cilexetil drug industry. This candesartan cilexetil drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The candesartan cilexetil drug market size has grown strongly in recent years. It will grow from $1.57 billion in 2024 to $1.67 billion in 2025 at a compound annual growth rate (CAGR) of 6%. The growth during the historic period can be attributed to the rising prevalence of hypertension, the increasing geriatric population, a higher incidence of chronic diseases, a greater focus on preventative care, and the growing healthcare expenditure.

The candesartan cilexetil drug market size is expected to see strong growth in the next few years. It will grow to $2.09 billion in 2029 at a compound annual growth rate (CAGR) of 5.8%. The growth during the forecast period can be attributed to the expansion of generic drug availability, the rising incidence of lifestyle-related diseases, government initiatives for affordable hypertension care, the increasing prevalence of cardiovascular diseases, and the growing adoption of combination therapies. Key trends in the forecast period include a shift toward generic candesartan formulations, the development of fixed-dose combination drugs, integration of digital health for hypertension monitoring, a growing focus on patient compliance, and increasing research on novel delivery mechanisms.

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.